Doctors' Answers to "Frequently Asked Questions" - Temazepan


These comments are made for the purpose of discussion and should NOT be used as recommendations for or against therapies or other treatments. An individual patient is always advised to consult their own physician.

Temazepan and Pregnancy
Question: The affects of recreational use on pregnancy in the first trimester in regards to the health of the baby if it was only used once but several pills totalling 50mg of temazepan all up. I delivered a baby several months ago and the mother was high on amphetamines at the time and had been using regularly during the pregnency. What defects could this child have when growing up. She is already quite an irratible baby.

Answer: Use of any drug during pregnancy can affect the embryo. Constant use of temazepan will generate an addicted baby. The best advice is to avoid all drugs during pregnancy. Amphetamines and cocaine are major problems currently. Unfortunately it appears that their children will pay with syndromes similar to the Alcholic Baby Syndrome. It clearly affects their cognition and ability to mentally develop-research is currently underway to follow these children long term and see if their development ever approaches the norm.

Temazepan Information
Question: Can you give me some basic information about the drug temazepam: e.g., its general uses, side effects, dosages, etc.

Answer: Temazepam is the generic name for the drug sold as Restoril. This is a benzodiazepine sedative usually used for sedation to aid sleep. However, it can be used for anxiety or general sedation. Long term use will be addicting. Usual side effects are drowsiness, headache, fatigue, lethargy; and dizziness. It is a drug that is similar to valium, librium etc. Its only difference is its half life and some minor structural changes.
Back to Drug InfoNet Home Page.

Back to Doctor FAQ main page.

Send your impressions, comments, thoughts, etc. to [email protected]
© 1996-97 DRUG INFONET, Inc. All rights reserved.
Last modified October 2, 1997